Molecular Basis for the Potent Inhibition of the Emerging Carbapenemase VCC-1 by Avibactam | Zendy

Chand S. Mangat | Zendy; Grishma Vadlamani | Zendy; Viktor Holicek | Zendy; Mitchell Chu | Zendy; Veronica L. C. Larmour | Zendy; David J. Vocadlo | Zendy; Michael R. Mulvey | Zendy; Brian L. Mark | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Molecular Basis for the Potent Inhibition of the Emerging Carbapenemase VCC-1 by Avibactam

Author(s) -

Chand S. Mangat,

Grishma Vadlamani,

Viktor Holicek,

Mitchell Chu,

Veronica L. C. Larmour,

David J. Vocadlo,

Michael R. Mulvey,

Brian L. Mark

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02112-18

Subject(s) - avibactam , microbiology and biotechnology , ertapenem , clavulanic acid , vibrio cholerae , biology , carbapenem , beta lactamase inhibitors , aztreonam , imipenem , pseudomonas aeruginosa , antibiotics , antibiotic resistance , bacteria , amoxicillin , genetics , ceftazidime

In 2016, we identified a new class A carbapenemase, VCC-1, in a nontoxigenicVibrio cholerae strain that had been isolated from retail shrimp imported into Canada for human consumption. Shortly thereafter, seven additional VCC-1-producingV. cholerae isolates were recovered along the German coastline.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research